Saturday, July 22, 2017 3:04:48 PM
Inventory means nothing if they can't sell it. If they don't sell the inventory it's just more debt.
Company needs to get sales with the pet spray and nyoxlyn (sorry for the spelling).
Then they need the drugs in the pipeline that are in trials to get approved and hopefully licensed.
If they can pull that off we got a monster winner but make no mistake if they don't execute what I just wrote than continued debt and convertible notes will kill this.
Let's also keep in mind that they are competing with BIG PHARMA too. Hopefully they can license to BIG PHARMA as opposed to competing with them.
I do think this is a worthwhile risk with huge reward potential so I'm hoping for the best for all of us
FEATURED Element79 Gold Corp Shares Further Advances With Chachas Community on Lucero Surface Rights, Provides Corporate Update • Oct 28, 2024 10:25 AM
VAYK Clarifies It Has No Business Connection to Persons Under SEC Charge • VAYK • Oct 28, 2024 11:59 AM
Vocodia Enters Medical Alert Industry with Innovative Emergency Response Pendant • VHAI • Oct 25, 2024 8:00 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Third Quarter 2024 • HYDI • Oct 24, 2024 11:18 AM
VAYK Asserts Goal of Q4 Operationally Profitable and Projects Major 2025 Launch • VAYK • Oct 24, 2024 10:40 AM
CBD Life Sciences Inc. (CBDL) Positioned for Significant Growth Amid Nationwide Marijuana Legalization Push • CBDL • Oct 24, 2024 7:07 AM